Results 11 to 20 of about 3,650 (207)
Use of Depot Medroxyprogesterone Acetate and Fracture Risk [PDF]
The Journal of Clinical Endocrinology & Metabolism, 2010 Depot medroxyprogesterone acetate (DMPA), which has a high rate of use among teenagers in Europe and the United States, has been associated with impaired bone mineral acquisition during adolescence and accelerated bone loss in later life. Studies on the association between DMPA use and fracture risk are limited.We aimed at evaluating the relationship ...
Meier, Christian +4 more
openaire +6 more sources
Indonesian Journal of Obstetrics and Gynecology, 2018 Objective: Cervical cancer is the second most prevalent cancer in women around the world and the most common cancer in women causing death. This study aims to analyze the connection between infection of human papilloma virus (HPV) 16/18 and cervical ...
Baharuddin Aras +4 more
doaj +3 more sources
Middle East Fertility Society Journal, 2016 Objective: This study was aimed to investigate the effect of combined vitamin C and E on serum leptin, visceral fat mass, and visceral fat oxidative stress in rats treated by depot-medroxyprogesterone acetate (DMPA).
Endang Sri Wahyuni +2 more
doaj +2 more sources
Vaginal Atrophy following Long-Term Depot Medroxyprogesterone Acetate Use: A Case Report
Case Reports in Obstetrics and Gynecology, 2013 Depot medroxyprogesterone acetate (DMPA) is a commonly used form of contraception, with noncontraceptive benefits for the user. The mode of action is through the suppression of ovulation. It leads to hypoestrogenism which causes dryness of the vagina and
Christie Walker, Shawky Z. A. Badawy
doaj +2 more sources
Depo-Provera (depot medroxyprogesterone acetate) use after bariatric surgery
Open Access Journal of Contraception, 2016 Clarissa Lam,1 Amitasrigowri S Murthy2,3 1New York University School of Medicine, 2Department of Obstetrics and Gynecology, Bellevue Hospital Center, New York University School of Medicine, 3New York University Langone Medical Center, New York,
Lam C, Murthy AS
doaj +1 more source
Indonesian Journal of Obstetrics and Gynecology, 2014 Objective: To determine the comparison of body mass index (BMI) among acceptors of injectable depot medroxyprogesterone acetate (DMPA) with levonorgestrel implant acceptors for 1 year and comparison of lipid profiles between depot medroxyprogesterone ...
Irwan Daido +2 more
doaj +3 more sources
Archives of Endocrinology and Metabolism, 2016 Objective The aim of this study was to evaluate for 12 months the changes of body weight using Depot Medroxyprogesterone Acetate (DMPA) and if these changes are related to inflammatory markers. Subjects and methods Twenty women of childbearing age who
Gisele Almeida Batista +6 more
doaj +2 more sources
Journal of Toxicology, 2016 A study was designed to investigate ameliorates effect of combined vitamins C and E able to against depot-medroxyprogesterone acetate- (DMPA-) induced ovarian oxidative stress in rat. Twenty-five female Wistar rats were divided into the following groups (
Atik Ismiyati +2 more
doaj +2 more sources
Incidence of Galactorrhea in Young Women Using Depot-Medroxyprogesterone Acetate [PDF]
The Scientific World Journal, 2006 Galactorrhea is rarely mentioned as a possible side effect of the use of Depot-Medroxyprogesterone Acetate (DMPA). Over the last few years, we have noticed an increased number of patients complaining of galactorrhea. A review of clinical data showed that
Hatim A. Omar +4 more
doaj +2 more sources
Depot medroxyprogesterone acetate injection as contraceptive method
International Journal of Reproduction, Contraception, Obstetrics and GynecologyBackground: Depot medroxyprogesterone acetate (DMPA) injection is a reversible longer acting contraceptive method. One injection every three months makes compliance better and lesser side effects makes this contraception acceptable. Methods: This is a prospective study done at our institute between July 2021 to September 2023.
Riya R. Patel +2 more
openaire +3 more sources